Skip to main content
Back to feed
HealthSingle-sourceMedium
5.2

UK NHS approves Enhertu for HER2-low advanced breast cancer after price deal

England's NHS will fund Enhertu for ~1,000 women/year with HER2-low advanced breast cancer after a pricing agreement, extending life for incurable patients. The deal resolves prior cost-effectiveness hurdles, marking a notable access expansion for a targeted therapy. Impact is primarily clinical and fiscal for the UK health system.

Guardian Worldabout 7 hours agoGBengCredibility 29%View source

Score Breakdown

Mosaic Score5.2
Confidence0.9
Significance0.5
Source credibility0.3

Intelligence Tags

#breast cancer#drug access#nhs#oncology#pharmaceutical pricing

Locations

England

Entities

country
Source

Related signals

8 found